Insights

Top broker gives its verdict on the ResMed (ASX:RMD) share price

Is there still time to buy ResMed shares?
The post Top broker gives its verdict on the ResMed (ASX:RMD) share price appeared first on The Motley Fool Australia. –

The ResMed Inc (ASX: RMD) share price is rising on Monday morning.

At the time of writing, the sleep treatment focused medical device company’s shares are up 2% to $38.04.

This follows a positive night of trade for the US-listed ResMed share price on Friday night.

Can the ResMed share price climb even higher?

One leading broker that believes the ResMed share price may have peaked for the time being is Goldman Sachs.

According to a note, the broker has retained its neutral rating and lifted its price target on the company’s shares to $36.20.

Based on the latest ResMed share price, this implies potential downside of almost 5% over the next 12 months.

What did Goldman say?

Goldman notes that ResMed expects an FY 2022 revenue benefit of US$300 million to US$350 million relating to the recall of rival Philip’s competing products. This is significantly less than the US$750 million to US$800 million of device sales Philips generates annually.

The broker believes that the constraint on further upside is more a function of supply than demand, due to component shortages. However, it also notes that Philips has previously stated that component shortages and distribution bottlenecks are surmountable. Therefore, it sees limited reason why ResMed could not achieve a similar outcome.

Earnings estimates upgraded

Goldman has upgraded its estimates to reflect this benefit and other items.

It commented: “We post +15% EBITDA upgrades in FY22E, primarily to account for a material increase in flow generator sales, but also additional mask sales (not included in the guided $300-350m tailwind). We also upgrade our FY23E EBITDA by +4% on the same drivers (net of cost upgrades), but we highlight inherent upside to these forecasts should execution of the recall and/or reputational impacts drag materially beyond 12 months.”

However, this isn’t enough for a more positive rating. It believes the ResMed share price is looking expensive at the current level.

Goldman explained: “Clearly, RMD has a substantial opportunity to capture sustainable share, but we believe the earnings upgrades that could follow today’s update may not justify US$11bn (A$15bn) of additional market capitalisation since mid-May (31-37x the guided FY22 revenue tailwind). Valuation of 32x NTM EV/EBITDA is now +54% vs. history, and we remain Neutral-rated.”

The post Top broker gives its verdict on the ResMed (ASX:RMD) share price appeared first on The Motley Fool Australia.

Should you invest $1,000 in ResMed right now?

Before you consider ResMed, you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and ResMed wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of May 24th 2021

More reading

ASX 200 rises, Betmakers soars, REA Group drops

Why BHP, Northern Star, REA, & ResMed shares are dropping

ASX 200 midday update: REA & ResMed results, Afterpay jumps

Why the ResMed (ASX:RMD) share price slumped even as profit jumped
How owning too much Afterpay (ASX:APT) was our biggest regret

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended ResMed. The Motley Fool Australia has recommended ResMed Inc. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!